Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGR Followed by Short-Cycle Cytarabine in First-Line Mantle Cell Lymphoma
NCT06504199Phase 2Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab, zanubrutinib, lenalidomide, cytarabine in mantle cell lymphoma (MCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jul 2024; status: active, not recruiting.
02
Drugs
obinutuzumabzanubrutiniblenalidomidecytarabine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06504199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504199.